A pivotal phase III trial of AU-011 for Uveal melanoma
Phase of Trial: Phase III
Latest Information Update: 15 Oct 2019
Price : $35 *
At a glance
- Drugs AU 011 (Primary)
- Indications Uveal melanoma
- Focus Registrational; Therapeutic Use
- Sponsors Aura Biosciences
- 15 Oct 2019 According to an Aura Biosciences media release, novel design of this study presented at at the American Academy of Ophthalmology (AAO) 2019 Annual Meeting, being held October 12-15, 2019 in San Francisco, CA.This study is expected to commence in the second half of 2020.
- 02 Apr 2019 According to an Arix Bioscience media release, the study is expected to start in H1 2020.
- 09 Nov 2018 New trial record